The claim that life expectancy is only 9 years after taking memantine is false. Memantine improves the symptoms of Alzheimer’s disease, and the life expectancy of patients is related to the condition and can be less than 9 years or several decades.
Memantine blocks neuronal damage caused by pathologically elevated glutamate concentrations. It is primarily used to treat moderate and severe Alzheimer’s dementia. If the patient’s condition is well controlled, life expectancy will be relatively longer. If the patient’s symptoms are severe, the life expectancy will be relatively shorter.
Alzheimer’s disease is a degenerative disease characterized by a decline in mental ability, with a progressive loss of self-life functions in the middle and late stages of the disease, and in severe cases, the patient may become bedridden. After the onset of the disease, life expectancy is slowed down by improving symptoms through aggressive medication and rehabilitation. Early management of the disease results in a relatively longer life expectancy.